Opendata, web and dolomites

IMMUTRAIN SIGNED

Training Network for the Immunotherapy of Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IMMUTRAIN project word cloud

Explore the words cloud of the IMMUTRAIN project. It provides you a very rough idea of what is the project "IMMUTRAIN" about.

cells    medicine    therapy    nucleic    antibody    tumor    individualized    union    forming    nine    cancer    industrial    immutrain    sectors    dramatically    experimental    skilled    stage    leaders    2013    match    complementary    placed    breakthrough    journal    expanding    accordingly    total    involvement    influence    integrate    acids    immunotherapies    seven    science    bispecific    decade    coming    synergies    patient    fifteen    create    actively    strategies    form    skills    highlighted    heralding    combinatorial    industry    dendritic    therapies    training    considerable    innovative    young    students    reinforced    immunotherapy    paradigm    academia    esr    outcome    rising    trials    monoclonal    efforts    occurring    constantly    clinical    sharpen    network    countries    therapeutic    antibodies    immune    academic    rationale    ph    diversified    death    care    immunomodulatory    prestigious    designed    incidence    experts    trained    groups    integral    acute   

Project "IMMUTRAIN" data sheet

The following table provides information about the project.

Coordinator
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN 

Organization address
address: GESCHWISTER SCHOLL PLATZ 1
city: MUENCHEN
postcode: 80539
website: www.uni-muenchen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.immutrain.eu
 Total cost 3˙627˙525 €
 EC max contribution 3˙627˙525 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2014
 Funding Scheme MSCA-ITN-ETN
 Starting year 2015
 Duration (year-month-day) from 2015-12-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) coordinator 996˙865.00
2    REGION HOVEDSTADEN DK (HILLEROD) participant 580˙163.00
3    FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III ES (MADRID) participant 495˙745.00
4    THE NOTTINGHAM TRENT UNIVERSITY UK (NOTTINGHAM) participant 273˙287.00
5    INSTITUT GUSTAVE ROUSSY FR (VILLEJUIF) participant 262˙875.00
6    MEDIZINISCHE UNIVERSITAT INNSBRUCK AT (INNSBRUCK) participant 255˙934.00
7    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 255˙374.00
8    ROCHE DIAGNOSTICS GMBH DE (MANNHEIM) participant 249˙216.00
9    ISTITUTO EUROPEO DI ONCOLOGIA SRL IT (MILANO) participant 143˙367.00
10    HUMANITAS UNIVERSITY IT (PIEVE EMANUELE) participant 114˙693.00

Map

 Project objective

In the European Union, cancer is the leading cause of death and the overall cancer incidence is still increasing. As a result of expanding efforts to improve cancer outcome, a main paradigm change is occurring in cancer therapy towards individualized medicine. Antibody-based therapies form an integral and constantly growing part of this approach. Antibody-based therapies will strongly influence the coming decade of cancer care. The importance of immunotherapy has been highlighted by the prestigious Science journal as “breakthrough of the year 2013”, heralding the rising importance of immunotherapy. Accordingly the need for well-trained and skilled researchers in academia and industry is dramatically increasing in this field. IMMUTRAIN is a training network bringing together experts in the fields of monoclonal antibodies, dendritic cells, T-cells and immunomodulatory nucleic acids with a considerable industrial involvement. The network comprises nine academic research groups and five industrial partners in a total of seven European countries. IMMUTRAIN will actively create synergies between those sectors by forming and promoting young researchers to match the challenges of immunotherapies. Particular focus will be placed on combinatorial therapies and on the new emerging field of bispecific antibodies used to target both the tumor and the patient´s immune system. Fifteen Ph. D. students (early stage researchers, ESR) reinforced by the project leaders will investigate innovative therapeutic strategies and provide the rationale for future clinical trials. Throughout their projects, ESR will learn to integrate academic and industrial aspects and will sharpen their experimental and complementary skills in a well-designed and diversified training program.

 Deliverables

List of deliverables.
One manuscript on the combination of antibodies with T cells submitted for publication Documents, reports 2020-03-06 16:55:36
One manuscript on new formulations of antibodies to activate immune cells submitted for publication Documents, reports 2020-03-06 16:55:40
One manuscript on the combination of antibodies with dendritic cell therapy submitted for publication Documents, reports 2020-03-06 16:55:36
One manuscript on the combination of antibodies with therapeutic nucleic acids submitted for publication Documents, reports 2020-03-06 16:55:42
IMMUTRAIN position paper Documents, reports 2020-03-06 16:55:34
supervisory board Other 2020-02-20 17:41:01
Reports on conferences on the homepage Documents, reports 2020-02-20 17:41:01

Take a look to the deliverables list in detail:  detailed list of IMMUTRAIN deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Jayakumar Vadakekolathu, Shaymaa Ismael Kadhim Al-Juboori, Catherine Johnson, Anne Schneider, Magdalena Elżbieta Buczek, Anna Di Biase, Alan Graham Pockley, Graham Roy Ball, Desmond George Powe, Tarik Regad
MTSS1 and SCAMP1 cooperate to prevent invasion in breast cancer
published pages: 9(3):344, ISSN: 2041-4889, DOI: 10.1038/s41419-018-0364-9
Cell Death & Disease 9/3 2020-02-20
2019 Luisa Barbato, Marco Bocchetti, Anna Di Biase, Tarik Regad
Cancer Stem Cells and Targeting Strategies
published pages: 926, ISSN: 2073-4409, DOI: 10.3390/cells8080926
Cells 8/8 2020-02-20
2018 Sebastian Kobold, Stanislav Pantelyushin, Felicitas Rataj, Johannes vom Berg
Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
published pages: , ISSN: 2234-943X, DOI: 10.3389/fonc.2018.00285
Frontiers in Oncology 8 2020-02-20
2019 Mohamed-Reda Benmebarek, Clara Karches, Bruno Cadilha, Stefanie Lesch, Stefan Endres, Sebastian Kobold
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
published pages: 1283, ISSN: 1422-0067, DOI: 10.3390/ijms20061283
International Journal of Molecular Sciences 20/6 2020-02-20
2017 David Olmeda, Daniela Cerezo-Wallis, Erica Riveiro-Falkenbach, Paula C. Pennacchi, Marta Contreras-Alcalde, Nuria Ibarz, Metehan Cifdaloz, Xavier Catena, Tonantzin G. Calvo, Estela Cañón, Direna Alonso-Curbelo, Javier Suarez, Lisa Osterloh, Osvaldo Graña, Francisca Mulero, Diego Megías, Marta Cañamero, Jorge L. Martínez-Torrecuadrada, Chandrani Mondal, Julie Di Martino, David Lora, Inés Mar
Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine
published pages: 676-680, ISSN: 0028-0836, DOI: 10.1038/nature22977
Nature 546/7660 2020-02-20
2019 Michael Ruzicka, Lars M. Koenig, Simone Formisano, Daniel F. R. Boehmer, Binje Vick, Eva-M. Heuer, Hanna Meinl, Lorenz Kocheise, Marcus Zeitlhöfler, Julia Ahlfeld, Sebastian Kobold, Stefan Endres, Marion Subklewe, Peter Duewell, Max Schnurr, Irmela Jeremias, Felix S. Lichtenegger, Simon Rothenfusser
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade
published pages: , ISSN: 0887-6924, DOI: 10.1038/s41375-019-0639-x
Leukemia 2020-02-20
2019 Clara H. Karches, Mohamed-Reda Benmebarek, Moritz L. Schmidbauer, Mathias Kurzay, Richard Klaus, Martina Geiger, Felicitas Rataj, Bruno L. Cadilha, Stefanie Lesch, Constanze Heise, Ramona Murr, Johannes vom Berg, Martin Jastroch, Daniel Lamp, Jian Ding, Peter Duewell, Gerhard Niederfellner, Claudio Sustmann, Stefan Endres, Christian Klein, Sebastian Kobold
Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy
published pages: 5890-5900, ISSN: 1078-0432, DOI: 10.1158/1078-0432.ccr-18-3927
Clinical Cancer Research 25/19 2020-02-20
2019 Lydia Bellmann, Giuseppe Cappellano, Johanna F. Schachtl‐Riess, Anastasia Prokopi, Athanasios Seretis, Daniela Ortner, Christoph H. Tripp, Constance E. Brinckerhoff, David W. Mullins, Patrizia Stoitzner
A TLR7 agonist strengthens T and NK cell function during BRAF‐targeted therapy in a preclinical melanoma model
published pages: 1409-1420, ISSN: 0020-7136, DOI: 10.1002/ijc.32777
International Journal of Cancer 146/5 2020-02-20
2019 Stefan Stoiber, Bruno L. Cadilha, Mohamed-Reda Benmebarek, Stefanie Lesch, Stefan Endres, Sebastian Kobold
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
published pages: 472, ISSN: 2073-4409, DOI: 10.3390/cells8050472
Cells 8/5 2020-02-20
2017 Cornelia Voigt, Peter May, Adrian Gottschlich, Anamarija Markota, Daniel Wenk, Inga Gerlach, Sebastian Voigt, Georgios T. Stathopoulos, Kristina A. M. Arendt, Constanze Heise, Felicitas Rataj, Klaus-Peter Janssen, Melanie Königshoff, Hauke Winter, Isabelle Himsl, Wolfgang E. Thasler, Max Schnurr, Simon Rothenfußer, Stefan Endres, Sebastian Kobold
Cancer cells induce interleukin-22 production from memory CD4 + T cells via interleukin-1 to promote tumor growth
published pages: 12994-12999, ISSN: 0027-8424, DOI: 10.1073/pnas.1705165114
Proceedings of the National Academy of Sciences 114/49 2020-02-20
2019 Diana Darowski, Christian Jost, Kay Stubenrauch, Uwe Wessels, Jörg Benz, Andreas Ehler, Anne Freimoser-Grundschober, Peter Brünker, Ekkehard Mössner, Pablo Umaña, Sebastian Kobold, Christian Klein
P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation
published pages: , ISSN: 1741-0126, DOI: 10.1093/protein/gzz027
Protein Engineering, Design and Selection 2020-02-20
2019 Philipp Metzger, Sabrina V. Kirchleitner, Michael Kluge, Lars M. Koenig, Christine Hörth, Carlotta A. Rambuscheck, Daniel Böhmer, Julia Ahlfeld, Sebastian Kobold, Caroline C. Friedel, Stefan Endres, Max Schnurr, Peter Duewell
Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer
published pages: 7:288, ISSN: 2051-1426, DOI: 10.1186/s40425-019-0778-7
Journal for ImmunoTherapy of Cancer 7/1 2020-02-20
2019 Torben Heise, Johan F. A. Pijnenborg, Christian Büll, Niek van Hilten, Esther D. Kers-Rebel, Natasja Balneger, Hidde Elferink, Gosse J. Adema, Thomas J. Boltje
Potent Metabolic Sialylation Inhibitors Based on C-5-Modified Fluorinated Sialic Acids
published pages: 1014-1021, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.8b01757
Journal of Medicinal Chemistry 62/2 2020-02-20
2019 Xiao Liu, Junjian Li, Bruno Loureiro Cadilha, Anamarija Markota, Cornelia Voigt, Zhe Huang, Peter P. Lin, Daisy D. Wang, Juncheng Dai, Gisela Kranz, Anna Krandick, Darko Libl, Horst Zitzelsberger, Isabella Zagorski, Herbert Braselmann, Min Pan, Sibo Zhu, Yuanchi Huang, Sebastian Niedermeyer, Christoph A. Reichel, Bernd Uhl, Daria Briukhovetska, Javier Suárez, Sebastian Kobold, Olivier Gires, Hong
Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis
published pages: eaav4275, ISSN: 2375-2548, DOI: 10.1126/sciadv.aav4275
Science Advances 5/6 2020-02-20
2018 Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, Connie P. M. Duong, Maryam Tidjani Alou, Romain Daillère, Aurélie Fluckiger, Meriem Messaoudene, Conrad Rauber, Maria P. Roberti, Marine Fidelle, Caroline Flament, Vichnou Poirier-Colame, Paule Opolon, Christophe Klein, Kristina Iribarren, Laura Mondragón, Nicolas Jacquelot, Bo Qu, Gladys Ferrere, Céline Clémenson, Laura Mezquita, Jordi Re
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
published pages: 91-97, ISSN: 0036-8075, DOI: 10.1126/science.aan3706
Science 359/6371 2020-02-20
2018 Christian Büll, Thomas J Boltje, Natasja Balneger, Sarah M Weischer, Melissa Wassink, Jasper J van Gemst, Victor R.L.J Bloemendal, Louis Boon, Johan van der Vlag, Torben Heise, Martijn H den Brok, Gosse J. Adema
Sialic acid blockade suppresses tumor growth by enhancing T cell-mediated tumor immunity
published pages: canres.3376.2017, ISSN: 0008-5472, DOI: 10.1158/0008-5472.can-17-3376
Cancer Research 2020-02-20
2019 Marlies J.W. Peeters, Donata Dulkeviciute, Arianna Draghi, Cathrin Ritter, Anne Rahbech, Signe K. Skadborg, Tina Seremet, Ana Micaela Carnaz Simões, Evelina Martinenaite, Hólmfridur R. Halldórsdóttir, Mads Hald Andersen, Gitte Holmen Olofsson, Inge Marie Svane, Lene Juel Rasmussen, Özcan Met, Jürgen C. Becker, Marco Donia, Claus Desler, Per thor Straten
MERTK Acts as a Costimulatory Receptor on Human CD8 + T Cells
published pages: 1472-1484, ISSN: 2326-6066, DOI: 10.1158/2326-6066.cir-18-0841
Cancer Immunology Research 7/9 2020-02-20
2018 Adrian Gottschlich, Stefan Endres, Sebastian Kobold
Can we use interleukin-1β blockade for lung cancer treatment?
published pages: S160-S164, ISSN: 2218-6751, DOI: 10.21037/tlcr.2018.03.15
Translational Lung Cancer Research 7/S2 2020-02-20

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUTRAIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUTRAIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

BIGMATH (2018)

Big Data Challenges for Mathematics

Read More  

ElectroPros (2019)

Training research pioneers by utilizing and validating the promise of electroporation for minimal invasive oncological treatments.

Read More  

DISTINCT (2019)

Dementia: Intersectorial Strategy for Training and Innovation Network for Current Technology (DISTINCT)

Read More